According to the hormone receptor status of breast tumor cells, ER-positive breast cancer has been found to have relatively high levels of RARα and to be sensitive to retinoids, whereas ER-negative tumors have low levels of RARα and were found to be resistant to retinoids [131,142]. This evidence concerns the gene RARA and breast neoplasm.